The New Biological Synthesis

By Clyde A. Hutchison III, Hamilton O. Smith, and J. Craig Venter FEATUREIs This Life?The New Biological Synthesis It's time to rewrite life's operating system Anything beyond the minimal gene set can be viewed as add on functions to improve adaptability and metabolic versatility.From top to bottom: Clyde A. Hutchinson is a distinguished investigator, Hamilton Smith is scientific director, and J. Craig Venter is

Written byClyde A. Hutchison III, Hamilton O. Smith, and J. Craig Venter
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Synthetic biologist views the genome as the cell's operating system. The hardware, including ribosomes and other parts of the translational and transcriptional apparatus, carry out the instructions contained within this OS. Traditional genetic techniques have allowed us to alter the code and alter the cell in useful and informative ways, but these are limited to manipulation of existing sequence. With a synthetic genome, this limitation disappears. Dramatic alterations of genetic content and arrangement become possible, and totally novel designer genes can be included. Designing and building synthetic genomes that function properly will be a true test of our understanding of cellular molecular biology.

At the Venter Institute we are designing and building a synthetic version of the Mycoplasma genitalium genome. With only 482 protein-coding genes and 43 RNA genes, this bacterium is the simplest known cell capable of independent growth and replication. Importantly, its 580-kilobase circular chromosome is small enough ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies